Lege Artis Medicinae

[BENEFICIAL EFFECT OF INSULIN DETEMIR ON THE BODY WEIGHT OF DIABETICS]

BECHER Péter

SEPTEMBER 19, 2007

Lege Artis Medicinae - 2007;17(08-09)

[Detemir is the newest base insulin analogue. In phase III trials and the PREDICTIVE study, the use of insulin detemir in various treatment regimens (basal-bolus or in combination with an oral antidiabetic) did not lead to weight gain in either types of diabetes, in contrast to what is usually observed with insulin therapy. Similar results were obtained when neutral protamine Hagedorn insulin or glargine were replaced by detemir, or insulin-naive patients received detemir as a new therapeutic regime. The mechanism of the beneficial effect on body weight is not clear yet. It may be related to the reduction in the number of hypoglycaemic episodes. It may also be associated with a stronger action of detemir on hepatocytes compared to peripheral tissues due to its acylation, which results in an effective suppression of hepatic glucose output without promoting lipogenesis in the adipocytes. Detemir reaches the insulin receptors of the hypothalamus faster than regular insulin, therefore, satiety develops in a shorter time. These hypotheses still require further studies.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Reduction in cholesterol using rosuvastatin therapy - MERCURY II trial]

NAGY Viktor

Lege Artis Medicinae

[Diseased or Possessed?]

BÁNFALVI Attila

Lege Artis Medicinae

[Getting Rid of Cigarette...]

VADÁSZ Imre

Lege Artis Medicinae

[Authorization and Marketing of Medicines in the European Union Member States]

BORVENDÉG János

Lege Artis Medicinae

[Interstitial Shadow in the Lung A Case Description in Images]

PÁPAY Judit, MOLDVAY Judit

All articles in the issue

Related contents

Lege Artis Medicinae

[Insulin analogues and pregnancy]

TAMÁS GYULA, KERÉNYI ZSUZSA

[Near-normoglycaemic metabolic control in pregnant women with diabetes - started before conception in pregestational diabetes - decreases the frequency of maternal and foetal complications. Such control can be achieved by using optimalised systems of insulin therapy. A number of (ultra)rapid and long-acting insulin analogues became available during the last decade, which - on the basis of theoretical considerations - might be used to maintain normoglycaemia. Summarising the data available today, the use of rapid insulin analogues (lispro, aspart) seem to be effective and safe during pregnancy. Some questions arise, however, about their modes of application. The use of long-acting insulin analogues in pregnancy is currently not indicated. Further trials are needed to prove their efficacy and safety in diabetic pregnancy.]

Lege Artis Medicinae

[THE LONG ACTING INSULIN ANALOGUE DETEMIR IN THE DIABETOLOGICAL PRACTICE: EVIDENCE AND POTENTIALS]

TAMÁS GYULA, KERÉNYI ZSUZSA

[Insulin detemir is a neutral, soluble, long-acting insulin analogue in which the amino acid threonineB30 has been removed and the LysB29 acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to dihexamerisate and reversibly bind to human albumin upon administration. This brand new principle (self association and albumin binding) ensures slow absorption and a prolonged and consistent metabolic effect without a marked peak for up to 24 hours in patients both with type 1 and type 2 diabetes mellitus. Results of large clinical trials have shown that detemir can be efficiently used as basal insulin, supplemented with human regular insulin or aspart insulin taken before the main meals, in both type 1 and type 2 diabetes. Available data clearly demonstrate that the use of this insulin is associated with decreased variability of the fasting blood glucose values. In some of the studies the risk of (mostly nocturnal) hypoglycaemic episodes also dropped. It is important to note that patients using insulin detemir gained less or no weight compared to the group of patients treated with neutral protamine Hagedorn (NPH) insulin. Evaluation of long-term and wide-spread application of detemir needs further observations. Such trials are being conducted worldwide.]

Clinical Neuroscience

Delirium due to the use of topical cyclopentolate hydrochloride

MAHMUT Atum, ERKAN Çelik, GÜRSOY Alagöz

Introduction - Our aim is to present a rare case where a child had delirium manifestation after instillation of cyclopentolate. Case presentation - A 7-year old patient was seen in our outpatient clinic, and cyclopentolate was dropped three times at 10 minutes intervals in both eyes. The patient suddenly developed behavioral disorders along with gait disturbance, and complained of visual hallucinations 20-25 minutes after the last drop. The patient was transferred to intensive care unit and 0.02 mg/kg IV. physostigmine was administered. The patient improved after minutes of onset of physostigmine, and was discharged with total recovery after 30 minutes. Conclusion - Delirium is a rare systemic side effect of cyclopentolate. The specific antidote is physostigmine, which can be used in severely agitated patients who are not responding to other therapies.